logo
logo
RLAY stock ticker logo

Relay Therapeutics, Inc.

NASDAQ•RLAY
CEO: Mr. Alexis A. Borisy A.M.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-07-16
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Contact Information
399 Binney Street, 2nd Floor, Cambridge, MA, 02139, United States
617-370-8837
www.relaytx.com
Market Cap
$1.89B
P/E (TTM)
-6.5
17.5
Dividend Yield
--
52W High
$11.43
52W Low
$1.78
52W Range
91%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$7.00M+0.00%
4-Quarter Trend

EPS

-$0.32+0.00%
4-Quarter Trend

FCF

-$44.87M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Significantly Reduced Net loss narrowed to $276.5M USD in 2025 from $337.7M USD in 2024, reflecting $61.2M USD improvement.
R&D Spending Streamlined Research spending decreased $57.7M USD to $261.4M USD in 2025 due to strategic pipeline streamlining efforts.
Lead Candidate Trial Progress Zovegalisib Phase 3 ReDiscover-2 Trial initiated Q2 2025; FDA granted Breakthrough Therapy designation in February 2026.
Strong Cash Position Maintained Cash, equivalents, and investments totaled $554.5M USD as of December 31, 2025, funding operations into 2029.

Risk Factors

Clinical Development Uncertainty Never completed large-scale pivotal trials; clinical outcomes remain uncertain, risking delays or failure to obtain regulatory approval.
Future Capital Requirements Development is capital-intensive; inability to raise needed funding forces delays, reductions, or elimination of development programs.
Competition and Market Acceptance Faces substantial competition; market acceptance hinges on efficacy, safety, pricing, and securing adequate third-party payor reimbursement.
Intellectual Property Protection Success depends on obtaining and maintaining broad patent protection; litigation risks could narrow scope or invalidate key IP rights.

Outlook

Advance PI3K Alpha Franchise Prioritize advancing Zovegalisib through Phase 3 trials aiming for broad patient population access in breast cancer and genetic disease.
Pipeline Progression Focus Progressing NRAS-selective inhibitor RLY-8161 and non-inhibitory chaperone for Fabry disease through early discovery stages.
Strategic Partnership Maximization Intend to selectively enter partnerships to maximize platform and pipeline value, accelerating development and commercialization efforts.
Manage Geopolitical/Economic Risks Monitor evolving economic conditions, regulatory changes, and geopolitical conflicts impacting supply chain, capital access, and operations.

Peer Comparison

Revenue (TTM)

SNDX stock ticker logoSNDX
$172.35M
+627.8%
XNCR stock ticker logoXNCR
$125.58M
+4.0%
CVAC stock ticker logoCVAC
$78.57M
-87.0%

Gross Margin (Latest Quarter)

PRME stock ticker logoPRME
4698.2%
-3591.0pp
SNDX stock ticker logoSNDX
102.3%
-13.9pp
CVAC stock ticker logoCVAC
99.3%
+0.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PRAX$6.41B-22.5-58.7%0.0%
SNDX$2.12B-7.3-206.6%65.4%
TNGX$1.99B-19.6-50.3%8.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-3.0%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026
|
EPS:-$0.36
|
Revenue:$3.38M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data